RT Journal Article
SR Electronic
T1 Antitumor Activity of Capecitabine and Bevacizumab Combination in a Human Estrogen Receptor-negative Breast Adenocarcinoma Xenograft Model
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 2279
OP 2287
VO 27
IS 4B
A1 HIGGINS, BRIAN
A1 KOLINSKY, KENNETH
A1 LINN, MICHAEL
A1 ADAMES, VIOLETA
A1 ZHANG, YU-E
A1 MOISA, CARLOS
A1 DUGAN, UTE
A1 HEIMBROOK, DAVID
A1 PACKMAN, KATHRYN
YR 2007
UL http://ar.iiarjournals.org/content/27/4B/2279.abstract
AB Background: Capecitabine and bevacizumab have each been shown to inhibit tumor growth. Their combination failed to improve survival in a phase III trial of metastatic breast cancer (MBC), although it should be noted patients had been heavily pretreated with anthracyclines and taxanes. Our aim was to evaluate whether combination treatment would increase tumor growth inhibition and survival in a breast cancer model. Materials and Methods: Mice bearing KPL-4 human estrogen receptor-negative breast adenocarcinoma xenografts were given capecitabine orally daily for 14 days at the maximum tolerated dose (MTD) or half MTD, alone or with 5 mg/kg intraperitoneal bevacizumab twice weekly. Results: Tumor growth inhibition (TGI) and increased life span (ILS) were superior in the combination groups versus monotherapy (p<0.05). TGI and ILS were significantly improved in the high-versus low-dose capecitabine combination (p<0.05). Conclusion: Capecitabine in combination with bevacizumab provides a basis for pursuing the combination for first-line treatment of MBC. Copyright© 2007 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved